Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study
ConclusionIncreased determination of HER2 and administration of trastuzumab have changed daily practice management of metastatic gastroesophageal cancer patients receiving palliative systemic therapy, and possibly contributed to their improved survival. Further increase in awareness of HER2 testing and trastuzumab administration may improve quality of care and patient outcomes.
Source: Gastric Cancer - Category: Gastroenterology Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Gastric (Stomach) Cancer | Gastroenterology | HER2 | Herceptin | Netherlands Health | Palliative | Pathology | Practice Management | Study